GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » Earnings Power Value (EPV)

Kontafarma China Holdings (HKSE:01312) Earnings Power Value (EPV) : HK$1.22 (As of Dec23)


View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings Earnings Power Value (EPV)?

As of Dec23, Kontafarma China Holdings's earnings power value is HK$1.22. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is 97.05

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Kontafarma China Holdings Earnings Power Value (EPV) Historical Data

The historical data trend for Kontafarma China Holdings's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings Earnings Power Value (EPV) Chart

Kontafarma China Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 2.22 2.51 1.99 1.22

Kontafarma China Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 - 1.99 - 1.22

Competitive Comparison of Kontafarma China Holdings's Earnings Power Value (EPV)

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kontafarma China Holdings's Earnings Power Value (EPV) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's Earnings Power Value (EPV) falls into.



Kontafarma China Holdings Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Kontafarma China Holdings's "Earning Power" Calculation:

Average of Last 5 Years Last Year
Revenue 887.3
DDA 137.8
Operating Margin % -1.40
SGA * 25% 126.2
Tax Rate % -1,335.93
Maintenance Capex 79.0
Cash and Cash Equivalents 87.7
Short-Term Debt 105.7
Long-Term Debt 228.1
Shares Outstanding (Diluted) 5,578.7

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -1.40%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = HK$887.3 Mil, Average Operating Margin = -1.40%, Average Adjusted SGA = 126.2,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 887.3 * -1.40% +126.2 = HK$113.859983344 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = -1,335.93%, and "Normalized" EBIT = HK$113.859983344 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 113.859983344 * ( 1 - -1,335.93% ) = HK$1634.9451044322 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 137.8 * 0.5 * -1,335.93% = HK$-920.744245868 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 1634.9451044322 + -920.744245868 = HK$714.20085856417 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Kontafarma China Holdings's Average Maintenance CAPEX = HK$79.0 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Kontafarma China Holdings's current cash and cash equivalent = HK$87.7 Mil.
Kontafarma China Holdings's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 228.1 + 105.7 = HK$333.823 Mil.
Kontafarma China Holdings's current Shares Outstanding (Diluted Average) = 5,578.7 Mil.

Kontafarma China Holdings's Earnings Power Value (EPV) for Dec23 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 714.20085856417 - 79.0)/ 9%+87.7-333.823 )/5,578.7
=1.22

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( 1.2210334945855-0.036 )/1.2210334945855
= 97.05%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


Kontafarma China Holdings  (HKSE:01312) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Kontafarma China Holdings Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kontafarma China Holdings (HKSE:01312) Business Description

Traded in Other Exchanges
N/A
Address
30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.
Executives
Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui 2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z 2201 Interest of corporation controlled by you
China Health Management Investment Limited 2101 Beneficial owner
Waranty Assets Management (hk) Limited 2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines